<DOC>
	<DOCNO>NCT00910273</DOCNO>
	<brief_summary>Study assess whether etanercept therapy able increase flow-mediated vasodilatation AS , whether etanercept modify intima-media thickness ( IMT ) patient</brief_summary>
	<brief_title>Effects Etanercept Heart , Veins Thickness Certain Major Arteries In Ankylosing Spondylitis Patients</brief_title>
	<detailed_description />
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>1 . Diagnosis AS , define Modified New York Criteria Ankylosing Spondylitis . 2 . AS active disease define Bath Ankylosing Spondylitis Disease Activity Index ( BASDAI , see Attachment 4 ) &gt; = 4 screen visit . 3 . Patients capable , opinion investigator , comply treatment schedule dose throughout 52 week 4 . Agreement male subject surgically sterile female subject surgically sterile postmenopausal use reliable method birth control duration study . 5 . Ability selfinject drug designee . 6 . Ability store injectable test article 2ºC 8ºC . 1 . Pregnancy confirm test take screen woman except surgically sterile least 1 year postmenopausal . Sexually active woman childbearing potential participating study must use medically acceptable form contraception need continued 15 day follow discontinuation test article .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>IMT evaluation AS patient treat etanercept</keyword>
</DOC>